P.111 In vivo hippocampal mGluR5 abnormalities predict MTLE post-surgical outcome. (June 2022)

• Record Type: Journal Article
• Authors: Lam, J; DuBois, JM; Rowley, J; Rousset, OG; González-Otárula, KA; Soucy, J; Massarweh, G; Hall, JA; Guiot, M; Zimmermann, M; Minuzzi, L; Rosa-Neto, P; Kobayashi, E
• Is Part Of: Canadian journal of neurological sciences. Volume 49(2022)Supplement 1
• Page Start: S37
• Page End: S37
• Publication Date: 2022-06
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Electronic journals; 616.8
• DOI: 10.1017/cjn.2022.204
• Languages: English
• ISSNs: 0317-1671

Abstract

Abstract : Background: PET imaging of [ 11 C]ABP688 shows reduced hippocampal mGluR5 availability in mesial temporal lobe epilepsy (MTLE) patients, however the relation with post-surgical outcomes is unclear. Here, we tested whether [ 11 C]ABP688 binding in hippocampal subfields vulnerable to glutamate excitotoxicity is related to post-surgical outcome. Methods: [ 11 C]ABP688-PET was obtained from 31 unilateral MTLE patients and 30 controls. Hippocampal subfields were automatically segmented into 1) CA1-3, 2) CA4/dentate gyrus (DG), 3) Subiculum and manually corrected. Partial volume corrected [ 11 C]ABP688 non-displaceable binding potential (BPND ) was calculated in the subfields and compared between seizure-free and non-seizure-free patients. Results: [ 11 C]ABP688 BPND was significantly reduced in ipsilateral CA1-3 & CA4/DG (p<0.001) compared to controls. No difference was seen in Subiculum. Ipsilateral CA1-3 [ 11 C]ABP688 BPND was lower in seizure-free (p=0.012; Engel Ia, n=13) vs non-seizure- free (Engel Ic-III, n=10) patients, and this effect was independent of subfield volume. In a subset of patients with [ 18 F]FDG-PET, CA1-3 [ 11 C]ABP688 BPND was significantly lower in seizure-free patients (p=0.03), while no difference was found for [ 18 F]FDG uptake. Conclusions: Reduced CA1-3 mGluR5 availability was associated with post-surgical seizure-freedom independent of atrophy and hypometabolism. Thus, [ 11 C]ABP688-PET may offer a potential biomarker for surgical outcomes and may be particularly relevant for pre-surgical workup in MRI- and [ 18 F]FDG-negative MTLE patients.